Immunology Stocks Gaining Momentum… Market Cap Surges Over $400 Million in Just One Day

Immunovant Inc. (NASDAQ: IMVT) closed at $24.73 on the Nasdaq on the 22nd, up 7.6%, pushing its market capitalization to roughly $5.0 billion (about KRW 6.8 trillion). In a single day, its market cap rose by approximately $415 million (around KRW 560 billion), and trading volume exceeded 1.3 million shares.

This follows a December public offering that raised about $550 million (roughly KRW 740 billion) and an additional $350 million (around KRW 470 billion) equity investment by its parent, Roivant Sciences—moves that market watchers say have fully equipped the company with both firepower and a robust pipeline.

A subsidiary of Roivant Sciences, Immunovant is advancing clinical programs targeting severe autoimmune diseases with its FcRn-targeting antibody IMVT-1402 and the anti-CD40L antibody batoclimab. IMVT-1402, in particular, is regarded as a core asset poised to enter pivotal trials across multiple indications.